pharma · wet macula degeneration · Chronic Urticaria
CuraTeQ Biologics s.r.o
CuraTeQ Biologics is a pharma organization headquartered in Hyderabad, IN. Primary therapeutic focus areas include wet macula degeneration, Chronic Urticaria. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s)
Hyderabad, IN HQ
2016 Founded
645 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Hyderabad, IN
- Founded
- 2016
- Employees
- 645
- Programs
- 2
- Drugs
- 6
- Patents
- 0
CR213-20
Phase 3 · small molecule · wet macula degeneration
CR213-20 for wet macula degeneration is a Phase 3 program (small_molecule) at CuraTeQ Biologics s.r.o with 1 ClinicalTrials.gov record(s).
Internal code CR213-20
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CuraTeQ Biologics s.r.o
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- wet macula degeneration
- Status
- active
- Trials
- 1